Importantly, pharmacological inhibitors of SK4 channels already exist and are developed for therapy of sickle‐cell anemia, asthma, autoimmune encephalomyelitis, immunosuppression, and ischemic stroke (Wulff & Kohler, 2013). The gene discussed is KCNN4; the disease is asthma.